IncellDx, based in Menlo Park, CA, is a leading single-cell diagnostic company dedicated to advancing Precision Medicine. They offer transformative diagnostic and prognostic clinical patient information through an innovative technology platform that enables simultaneous cell classification and single-cell analysis of proteomic and genomic biomarkers. By combining proprietary molecular diagnostics with cellular analysis, they aim to revolutionize healthcare one cell at a time.

Their product portfolio includes the CE-IVD HPV OncoTect 3Dx™, a unique quantitative cell-based assay for in vitro diagnostics that measures both mRNA E6 and E7, providing valuable information for cervical cancer diagnosis. They also offer Cytokine and Receptor Occupancy Kits for comprehensive analysis. In terms of news, IncellDx has received clinical approval for their next-gen HPV/Cervical Cancer Assay (HPV OncoTect 3Dx) from the Costa Rican Ministry of Health.

They have also presented abstracts at various prestigious conferences and have been featured in the media. With a commitment to precision medicine and accurate diagnostics, IncellDx is at the forefront of improving clinical decision-making for physicians